These diagnoses are usually distinguished by very high plasma 17-hydroxyprogesterone (170HP) in CAH. However, 170HP from adrenal rests may not be suppressible with glucocorticoids, and these ...

The study enrolled 28 patients across 3 dose cohorts with classic CAH on a stable dose of glucocorticoid replacement. Primary endpoints included change from baseline in morning serum androstenedione ...

CAH, a group of genetic disorders affecting adrenal ... A similar statistically significant decline was seen for morning serum 17-hydroxyprogesterone (17-OHP), a secondary endpoint of the trial.

substantial and sustained statistically significant reductions in key CAH disease related biomarkers, including androstenedione and 17-hydroxyprogesterone, in a diverse population. Atumelnant is ...